Non-exclusive discount agreements for medicines containing natalizumab under an open-house model

Summary

The tender concerns non-exclusive discount agreements for medicines containing natalizumab under an open-house participation model. Pharmaceutical companies may participate if they meet and accept the participation conditions. There will be no individual contract negotiations, and no exclusive supply rights will be granted. Demand-dependent purchasing volumes are unknown, and no minimum purchase quantity is guaranteed. To access the participation documents, companies must request access to the DTVP project area and await the contracting authority’s approval. Participation applications may first be submitted by 4 November 2026; subsequent deadlines are set out in the project area. The agreement ends no later than 30 November 2027, although the contracting authority may end the procedure earlier. Submission requirements and participation conditions should be checked in the official tender documents.